期刊文献+

PET-CT在恶性淋巴瘤治疗后疗效评价中的应用 被引量:5

Application of PET-CT in evaluation of response to treatment in malignant lymphoma
下载PDF
导出
摘要 目的研究PET-CT在恶性淋巴瘤治疗后疗效评价中的应用价值。方法回顾性分析24例恶性淋巴瘤患者18F-FDGPET-CT结果,其中4例为治疗前后均进行了PET-CT显像,另外20例为治疗后患者,对比治疗前后的影像检查结果,判定治疗效果。结果 24例患者中18例有不同程度好转,5例有逆转,另有1例原发部位好转,但有其他脏器及淋巴结浸润(进展)。结论 PET-CT检查对于恶性淋巴瘤治疗后的疗效评价敏感、准确,对于继续治疗或二次治疗方案的选择具有重要的指导意义。 Objective To evaluate the value of PET-CT in evaluation of response to treatment in malignant lymphoma. Methods Twenty-four post-treatment patients with malignant lymphoma were studied retrospectively, 4 cases had PET-CT before and after treatment, 20 cases had PET-CT after treatment. PET-CT images after therapy were compared with other images, the final diagnosis were made. Results According to the PET-CT images, in 24 post-treatment patients with malignant lymphoma, 18 cases improved or partly improved, 5 cases were in progressing, and 1 case recurred after relief. Conclusion PET-CT is sensitive and accurate in evaluation of response to treatment in malignant lymphoma, there are significant values in its treatment directing and prognosis assessing in the malignant lymphoma.
作者 刘太峰
出处 《中国当代医药》 2012年第26期111-112,共2页 China Modern Medicine
关键词 淋巴瘤 PET-CT 恶性淋巴瘤 应用 Lymphoma PET-CT Malignant lymphoma Application
  • 引文网络
  • 相关文献

参考文献9

  • 1Cerci J J,Trindade E,Buecheri V,et al. Consistency of FDG-PET accu-racy and cost -effectiveness in initial staging of patients with Hodgkinlymphoma across jurisdictions^]. Clin Lymphoma Myeloma Leuk, 2011,11(4):314-320.
  • 2Wu X, Dastidar P, Pertovaara H,et al. Early Treatment Response Evalu-ation in Patients with Difuse Large B -Cell Lymphoma -A Pilot StudyComparing Volumetric MRI and PET/CT[J]. Mol Imaging Biol,2010,25(8):22-24.
  • 3田嘉禾.PET在淋巴瘤诊断方面的应用[J].实用肿瘤杂志,2005,20(2):102-105. 被引量:7
  • 4陈伟华,冷吉艳.^(18)F-FDG PET-CT显像对恶性淋巴瘤诊断和分期中的临床应用价值[J].中国实验诊断学,2010,14(5):682-684. 被引量:8
  • 5王瑜,杨小丰,张云,曹务成,任蓉,艾娜,柴黎明.^(18)F-FDG PET/CT显像对淋巴瘤的诊断及疗效观察[J].新疆医学,2010,39(2):1-3. 被引量:2
  • 6Crocchiolo R,Fallanca F’Giovacchini G,et al. Role of 18FDG-PET/CTin detecting relapse during follow-up of patients with Hodgkin's lym-phoma[J]. Ann Hematol, 2009,88 (12) : 1229-1236.
  • 7Baba S,Abe K,lsoda T,et al. Impact of FDG-PET/CT in the manage-ment of lymphoma[J]. Ann Nucl Med,2011,29( 10) :Epub ahead of print.
  • 8Hutchings M, Barrington S F. PET/CT for therapy response assessmentin lymphoma[J]. J Nucl Med ,2009,50(Suppl 1 ) :21-30.
  • 9Cheson BD’Pfistner B’Juweid ME ,et al. Revised response criteria formalignant lymphoma[J]. J Clin Oneol, 2007,25 : 579-586.

二级参考文献15

  • 1田嘉禾.PET在淋巴瘤诊断方面的应用[J].实用肿瘤杂志,2005,20(2):102-105. 被引量:7
  • 2李向东,尹吉林,王卓才,王欣璐,全江涛,欧阳习,蔡超,郑辉.^(18)F-FDG PET/CT显像诊断恶性淋巴瘤的临床价值[J].广东医学,2007,28(7):1090-1091. 被引量:3
  • 3谢毅.淋巴瘤.内科学.6版.北京:人民卫生出版社,2005:619-630.
  • 4Potential pitfalls of 18F-FDG PET in a large series of patients treated for malignant lymphoma:prevalence and scan interpretation.Nucl med Commun,2005,26(8):689-694.
  • 5Bare R,Hostman K,Altehoefer C,et al.18F-FDG PET to assess local effect of radiation or chemotherapy in patients with malignant lymphoma.J Nucl Med,1991.27:56-58.
  • 6Hoekstra OS,Ossenkoppele GJ,Golding R,et al.Early treatment response in malignant lymphoma as determined by planar 18F-fluorodeoxyglucose scintigraph.J Nucl Med,1993,34:1706-1710.
  • 7Spaepen K,Stroobants S,Dupont P,et al.Early restaging positron emission tomography with 18F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma.Ann Oncol,2002,13:1356-1363.
  • 8Dittmann H,Sokler M,Kollmannsberger C,et al.Comparison of 18F-FDG PET with CT SCanS in the evaluation of patients with residual and recurrent Hodgkin's lymphoma.Oncol Rep,2001,8:1393-1399.
  • 9唐惟瑜,王凤英,朱雄增,等.恶性淋巴瘤.汤钊猷主编.现代肿瘤学[M].第2版.上海:上海医科大学出版社,2000.1290-1327.
  • 10Rodriguez M.Computed tomography,magnetic resonance imaging and positron emission tomography in non-Hodgkin's lymphoma[J].Acta Radiol,1998,417(Suppl):1.

共引文献14

同被引文献103

  • 1王新荣.胸水ADA、CEA、CA125、CA153水平在结核性与恶性胸水中的表达与意义[J].中国老年学杂志,2014,34(12):3290-3292. 被引量:8
  • 2刘岚.鼻咽癌放疗后复发与疗后其他改变的CT鉴别诊断[J].江西医药,2007,42(1):65-66. 被引量:3
  • 3花宁,陈立光.气相色谱法直接测量^(18)F-FDG中Kryptofix 2.2.2的含量[J].同位素,2007,20(2):105-107. 被引量:14
  • 4Cheson BD,Pfistner B,Juweid ME, et al. Revised response crite- ria for malignant lymphoma[J]. J Clin Oncol, 2007,25 (5) : 579- 586.
  • 5Whiting P, Rut)es AW, Reitsma JB, et aL The development of QUADAS:a tool for the quality assessment of studies of diag- nostic accuracy included in systematic reviews[-J]. BMC Med Res Methodol, 2003,3,25.
  • 6la Fougre C,Pfluger T,Sehneider V,et al. Restaging ofpatients with lymphoma. Comparison of low dose CT (20 mAs) with con- trast enhanced diagnostic CT in combined E18F]-FDG PET/CT [J]. Nuklearmedizin, 2008,47 ( 1 ) : 37-42.
  • 7Karantanis D, Subramaniam RM, Peller PJ, et al. The value of [-(18) F] fluorodeoxyglucose positron emission tomography/ computed tomography in extranodal natural killer/T-cell lym- phoma[-J]. Clin Lymphoma Myeloma,2008,8(2) :94-99.
  • 8Karantanis D, Durski JM, Lowe VJ, et al. 18F-FDG PET and PET/CT in Burkitt' s lymphoma[J/CD]. Eur J Radiol, 2010,75(1):e68-73.
  • 9Mikhaeel NG,Timothy AR, Hain SF,et al. 18-FDG-PET for the assessment of residual masses on CT following treatment of lym- phomas[-J]. Ann Oncol, 2000,11 Suppl 1 : 147-150.
  • 10Naumann R,Vaie A,Beuthien-Baumann B,et al. Prognostic value of positron emission tomography in the evaluation of post-treat- ment residual mass in patients with Hodgkin's disease and non- Hodgkin's lymphoma[-J]. Br J Haematol, 2001,115 (4) 793- 800.

引证文献5

二级引证文献10

;
使用帮助 返回顶部